Dark

IMAB
I-MAB
stock NASDAQ ADR

Market Open

May 9, 2025 1:37:27 PM EDT

0.8800USD-0.545%(0.0000)75,049

0.8400Bid 0.8800Ask 0.0400Spread

Pre-market

May 6, 2025 8:45:30 AM EDT

0.8800USD0.000%(0.0000)0

After-hours

May 6, 2025 4:13:30 PM EDT

0.9058USD+1.650%(+0.0147)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 28, 2022

08:08AM EST I-Mab Signs Partnership Agreement In Hangzhou Qiantang New Area Benzinga

08:01AM EST I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate PR Newswire

Jan 26, 2022

01:13PM EST New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 Bamboo Works Special Report Benzinga

Jan 18, 2022

08:27AM EST I-Mab: First Patient Dosed In China Phase 2 Trial Of Lemzoparlimab With Toripalimab With Advanced Solid Tumors RTTNews

08:26AM EST I-Mab Announces First Patient Dosed In China Phase 2 Combination Trial Of Lemzoparlimab With Toripalimab In Patients With Advanced Solid Tumors Benzinga

08:02AM EST I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of PR Newswire

Jan 14, 2022

08:01AM EST I-Mab Announces Execution of Senior Management Team Share Purchase Plan PR Newswire

Jan 13, 2022

12:55PM EST Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares Benzinga

Jan 12, 2022

08:05AM EST I-Mab Reports First Patient Dosed In China Phase 2 Trial Of Efineptakin Alfa-Pembrolizumab In Advanced Solid Tumors RTTNews

08:03AM EST I-Mab Announces First Patient Dosed In China Phase 2 Clinical Trial Of Efineptakin Alfa In Combination With Pembrolizumab In Advanced Solid Tumors Benzinga

08:01AM EST Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors PR Newswire

Jan 6, 2022

08:02AM EST I-Mab Announces Senior Management Team Share Purchase Plan PR Newswire

Dec 31, 2021

08:01AM EST I-Mab Announces Upcoming Participation at January Conferences PR Newswire

Dec 27, 2021

08:02AM EST I-Mab Unveils IND Approval From China NMPA For Phase 2 Trial Of Enoblituzumab With Pembrolizumab In Solid Tumors RTTNews

08:01AM EST I-Mab Announces IND Approval From China NMPA For Phase 2 Clinical Trial Of Enoblituzumab In Combination With Pembrolizumab In Solid Tumors Benzinga

08:00AM EST I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of PR Newswire

Dec 20, 2021

08:21AM EST I-Mab Announces Founder And Chairman Dr. Jingwu Zang Named Acting Chief Executive Officer Benzinga

08:01AM EST I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline PR Newswire

Dec 15, 2021

08:12AM EST I-Mab Receives IND Approval For Phase 1 Trial Of Bispecific Antibody TJ-CD4B In Solid Tumors In China RTTNews

08:04AM EST I-Mab Receives IND Approval For Phase 1 Clinical Trial Of Bispecific Antibody TJ-CD4B In Solid Tumors In China Benzinga

08:02AM EST I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody PR Newswire

Dec 14, 2021

06:10AM EST I-Mab Highlights ASH Presentation Benzinga

06:02AM EST I-Mab Presents Interim Data Of Lemzoparlimab With Rituximab In Relapsed And Refractory Non-Hodgkin Lymphoma At ASH RTTNews

06:01AM EST I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with PR Newswire

Dec 9, 2021

09:47PM EST I-Mab To Hold Dec. 14 Investor Call To Present Clinical Data Of Lemzoparlimab In Combination With Rituximab In Non-Hodgkins's Lymphoma Benzinga

08:02AM EST I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab PR Newswire

Dec 8, 2021

08:09AM EST I-Mab : First Patient Dosed In U.S. Phase 1 Study Of Protollin For Treatment Of Alzheimer's Disease RTTNews

08:03AM EST I-Mab Announces First Patient Dosed In US Phase 1 Study Of Protollin For The Treatment Of Alzheimer's Disease Benzinga

08:01AM EST I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the PR Newswire

Dec 7, 2021

08:06AM EST I-Mab To Pursue Dual Listing Plan On Main Board Of The Stock Exchange Of Hong Kong RTTNews

08:06AM EST I-Mab To Pursue Dual Listing Plan On The Main Board Of The Stock Exchange Of Hong Kong Limited Benzinga

08:03AM EST I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of PR Newswire

Dec 3, 2021

08:03AM EST I-Mab Says First Two Patients Dosed In U.S. Phase 2 Trial Of Uliledlimab - Atezolizumab On Solid Tumors RTTNews

08:02AM EST I-Mab Announces First 2 Patients Dosed In U.S. Phase 2 Combination Trial Of Uliledlimab With Atezolizumab In Patients With Selected Advanced Solid Tumors Benzinga

08:00AM EST I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of PR Newswire

Nov 10, 2021

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

05:53AM EST I-Mab and Jumpcan Announced Strategic Commercial Partnership on Eftansomatropin Alfa Benzinga

04:46AM EST Jumpcan, I-Mab Sign Commercial Partnership On Eftansomatropin Alfa; Jumpcan To Pay About $315 Mln To I-Mab RTTNews

04:30AM EST I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin PR Newswire

Nov 9, 2021

08:11AM EST I-Mab And ABL Bio Report Preclinical Data Of 4-1BB-targeting Bispecific Antibodies RTTNews

08:05AM EST I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific PR Newswire

Nov 8, 2021

08:30AM EST DayDayCook (DDC), a leading content driven direct-to-consumer brand in China, today announces the addition of three new independent directors to its Board of Directors: Conor Chia-Hung Yang, Matthew Gene Mouw, and Sam Shih. DDC also appointed a new advisor, Malik Sadiq to its Advisory Board. GlobeNewswire Inc

08:19AM EST I-Mab, Roche Diagnostics Announce Strategic Collaboration To Co-Develop Companion Diagnostics Solutions For I-Mab's Innovative Pipeline At 4th CIIE; Terms Not Disclosed Benzinga

08:02AM EST Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE PR Newswire

08:00AM EST DDC Enterprise Limited and Ace Global Business Acquisition Limited GlobeNewswire Inc

Nov 4, 2021

09:01AM EDT I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab PR Newswire

Nov 3, 2021

08:02AM EDT I-Mab Announces Upcoming Participation at November Conferences PR Newswire

Nov 1, 2021

08:11AM EDT I-Mab Appoints John Long As CFO And Jielun Zhu As Chief Strategy Officer RTTNews

08:03AM EDT I-Mab Names John Long As CFO Benzinga

08:02AM EDT I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and PR Newswire

04:40AM EDT Needham Maintains Buy on I-MAB, Raises Price Target to $85 Benzinga

Oct 26, 2021

08:18AM EDT I-Mab Announces Strategic Partnership With Sinopharm In Preparation For Launch Of Its Innovative Assets In China Benzinga

08:12AM EDT I-Mab Says On Track To Submit BLA For Third Line Multiple Myeloma Treatment By Q4 RTTNews

08:01AM EDT I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch PR Newswire

Oct 22, 2021

08:07AM EDT I-Mab To Establish New Site Focusing On Translational Medicine And Formulation Research In San Diego RTTNews

08:01AM EDT I-Mab Expands U.S. Footprint with New R&D Site in San Diego PR Newswire

Oct 18, 2021

08:17AM EDT I-Mab Announces IND Approval For Phase 2 Clinical Trial Of Efineptakin Alfa In Combination With PD-1 Therapy In China Benzinga

08:15AM EDT I-Mab Announces IND Approval For Phase 2 Trial Of Efineptakin Alfa In Combination With PD-1 Therapy In China RTTNews

08:01AM EDT I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in PR Newswire

Oct 13, 2021

01:38PM EDT I-Mab Reports Completion Of Patient Enrollment In Phase 3 Trial Of Felzartamab (TJ202) In Combo With Lenalidomide As Second-Line Therapy In Patients With Multiple Myeloma Benzinga

08:12AM EDT I-Mab Advances Late-stage Development Of Its Differentiated CD38 Antibody Felzartamab In China RTTNews

08:01AM EDT I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody PR Newswire

Oct 5, 2021

08:11AM EDT I-Mab And ABL Bio To Present Preclinical Data Of TJ-CD4B/ABL111 And TJ-L14B/ABL503 At 2021 SITC Annual Meeting RTTNews

08:03AM EDT I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and PR Newswire

08:02AM EDT I-Mab And ABL Bio To Present Preclinical Data Of TJ-CD4B/ABL111 And TJ-L14B/ABL503 At 2021 SITC Annual Meeting Nov. 12-14 Benzinga

Oct 1, 2021

08:01AM EDT I-Mab Announces Upcoming Participation at October Conferences PR Newswire

Sep 30, 2021

08:03AM EDT I-Mab Provides Clinical Updates Of Differentiated CD47 Antibody Lemzoparlimab Benzinga

08:00AM EDT I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 PR Newswire

Sep 28, 2021

08:54AM EDT I-Mab (IMAB) said the Center for Drug Evaluation of China National Medical Products Administration has accepted the company's IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors. The phase 2 trial will evaluate the efficacy of the combination of enoblituzumab and pembrolizumab. RTTNews

08:13AM EDT I-Mab : China Accepts IND Application For Phase 2 Trial Of Enoblituzumab-Pembrolizumab In Solid Tumors; Stock Up RTTNews

08:02AM EDT I-Mab Announces Acceptance Of IND Application From China NMPA For Phase 2 Clinical Trial Of Enoblituzumab In Combination With Pembrolizumab In Solid Tumors Benzinga

08:00AM EDT Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors PR Newswire

Sep 13, 2021

08:01AM EDT I-Mab Added to FTSE ESG Index Series PR Newswire

Sep 7, 2021

10:02AM EDT Shares of I-Mab (IMAB) is currently trading at $79.17, up $7.47 or 10.43%, with trading volume of 208K versus an average volume of 587K shares. The stock has been trading between $32.64 and $85.40 for the past one year. RTTNews

Sep 2, 2021

08:04AM EDT I-Mab Added To FTSE Russell Global Equity Index Series Benzinga

Sep 1, 2021

07:45AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

06:15AM EDT HC Wainwright & Co. Maintains Buy on I-MAB, Raises Price Target to $95 Benzinga

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

06:07AM EDT I-Mab H1 Loss Per Share RMB 6.38 Vs Loss RMB 4.78 Last Year RTTNews

06:03AM EDT I-Mab 1H EPS $(2.28) Benzinga

06:00AM EDT I-Mab Provides Business and Corporate Updates and Reports Financial Results for PR Newswire

Aug 30, 2021

08:01AM EDT I-Mab Announces Upcoming Participation at September Conferences PR Newswire

Aug 19, 2021

07:01AM EDT I-Mab Announces Establishment of Environmental, Social and Governance Committee PR Newswire

Aug 17, 2021

08:01AM EDT I-Mab to Provide Business and Corporate Updates and Report Financial Results PR Newswire

Aug 11, 2021

08:30AM EDT I-Mab (IMAB) announced positive interim data from its U.S. phase 2/3 study of plonmarlimab for the treatment of cytokine release syndrome or CRS in patients with severe COVID-19. RTTNews

08:11AM EDT I-Mab Reports Positive Interim Analysis From Phase 2/3 Study Of GM-CSF Antibody Plonmarlimab To Treat Severe COVID-19 RTTNews

08:01AM EDT I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab to Treat Patients with Severe COVID-19; Co. Reports 'treatment was well tolerated with no significant safety concerns in patients with severe COVID-19' Benzinga

08:01AM EDT I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF PR Newswire

Jul 30, 2021

09:32AM EDT I-Mab To Start Testing Alzheimer's Candidate In Human Trials Benzinga

08:33AM EDT The U.S. Food and Drug Administration has cleared the Investigational New Drug submission for Protollin, an investigational drug to treat Alzheimer's disease, enabling a Phase 1 clinical trial to be initiated, I-Mab (IMAB) said in a statement. RTTNews

08:03AM EDT I-Mab Announces IND Approval By FDA To Initiate Phase 1 Study For Protollin For Treatment Of Alzheimer's Disease RTTNews

08:02AM EDT I-Mab Reports FDA Approved Its Investigational New Drug To Initiate Phase 1 Study For Protollin For Treatment Of Alzheimer's Disease Benzinga

08:00AM EDT I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for PR Newswire

Jul 29, 2021

08:13AM EDT I-Mab Reports Renewed Its Buyback Plan For Up To $40M Benzinga

08:02AM EDT I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the PR Newswire

Jul 28, 2021

08:04AM EDT I-Mab : China Accepts IND For Phase 2 Trial Of Efineptakin RTTNews

07:37AM EDT I-Mab Announces IND Acceptance For Phase 2 Trial Of Efineptakin Alfa In Combination With PD-1 Therapy In China RTTNews

07:16AM EDT I-Mab Reports Investigational New Drug Application For Phase 2 Trial Of Efineptakin Alfa In Combo With PD-1 Therapy In China Benzinga

07:15AM EDT I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa PR Newswire

Jul 27, 2021

11:13AM EDT I-Mab Reports Board Approved Prelim. Proposal For Potential Dual Listing Of Co.'s Shares On Shanghai's Science And Technology Innovation Board, for Listing Tutoring Deal Between Co., Sponsor China Int'l. Capital Corp. Benzinga

Jul 9, 2021

09:02AM EDT ABL Bio Announces Publication of Preclinical Data Of ABL503/TJ-L14B. BZ NOTE: ABL503 Was Jointly Developed With I-Mab Benzinga

08:03AM EDT I-Mab Signs Two New Collaborations With Immorna And neoX Biotech; Both Partner Companies To Receive Undisclosed Upfront And/Or Milestone Payments Benzinga

08:03AM EDT I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics PR Newswire

Jul 1, 2021

08:11AM EDT I-Mab Announces Multiple Advancements Of 4-1BB Bispecific Antibody Portfolio Benzinga

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

08:01AM EDT I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio PR Newswire

Jun 30, 2021

08:00AM EDT I-Mab Honored with Top Rankings by Institutional Investor PR Newswire

Jun 29, 2021

08:02AM EDT I-Mab Announces Upcoming Participation at July Conference PR Newswire

Jun 25, 2021

08:30AM EDT I-Mab (IMAB) said that the Center for Drug Evaluation or CDE of the China National Medical Products Administration or NMPA has approved the Investigational New Drug or IND application to initiate a phase 1b trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus or SLE. RTTNews

08:10AM EDT I-Mab: China NMPA Approves IND Application To Begin Phase 1b Trial Of Felzartamab In SLE RTTNews

08:01AM EDT I-Mab Announces China NMPA Approval For Phase 1b Trial Of Felzartamab In Systemic Lupus Erythematosus Benzinga

08:01AM EDT I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in PR Newswire

Jun 21, 2021

08:21AM EDT I-Mab Appoints Andrew Zhu To Scientific Advisory Board RTTNews

08:01AM EDT I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to PR Newswire

Jun 10, 2021

08:33AM EDT Cantor Fitzgerald Maintains Overweight on I-MAB, Raises Price Target to $90 Benzinga

Jun 2, 2021

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2021 Benzinga

08:01AM EDT I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly PR Newswire

07:57AM EDT Daiwa Capital Initiates Coverage On I-MAB with Buy Rating Benzinga

Jun 1, 2021

08:16AM EDT I-Mab Appoints Ruyi He And Rong Shao To Board RTTNews

08:01AM EDT I-Mab Appoints Ruyi He and Rong Shao to Board of Directors PR Newswire

May 28, 2021

12:21PM EDT Mid-Day Market Update: Yext Surges Following Upbeat Q1 Results; 1847 Goedeker Shares Slide Benzinga

08:02AM EDT The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq Benzinga

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

08:01AM EDT I-Mab Announces Upcoming Participation at June Conferences PR Newswire

May 21, 2021

07:26AM EDT The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying Benzinga

May 20, 2021

06:17AM EDT I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings Benzinga

May 19, 2021

06:00PM EDT I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab PR Newswire

06:30AM EDT ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Neil Warma, MBA, to its Board of Directors with immediate effect. GlobeNewswire Inc

May 18, 2021

08:15AM EDT I-Mab Doses First Patient In China Phase 2 Trial Of Lemzoparlimab With Azacitidine In Patients With AML Or MDS RTTNews

08:02AM EDT I-Mab Announces First Patient Dosed In China Phase 2 Combination Trial Of Lemzoparlimab With Azacitidine In Patients With Acute Myeloid Leukemia Or Myelodysplastic Syndrome Benzinga

08:01AM EDT Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome PR Newswire

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

May 14, 2021

07:00AM EDT ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (ProMIS or the Company), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2021. GlobeNewswire Inc

May 13, 2021

08:00AM EDT I-Mab Added to MSCI China Index PR Newswire

Apr 29, 2021

08:00AM EDT I-Mab Announces Upcoming Participation at May Conferences PR Newswire

Apr 28, 2021

08:02AM EDT I-Mab Filed 2020 Annual Report on Form 20-F PR Newswire

Apr 26, 2021

09:58AM EDT I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study Benzinga

07:08AM EDT I-Mab Announces Positive Topline Phase 2 Results For Olamkicept In Ulcerative Colitis RTTNews

07:04AM EDT I-Mab Reports Topline Phase 2 Results For Oalmkicept In Ulcerative Colitis: Met Both Primary, Key Secondary Endpoints Benzinga

07:01AM EDT I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative PR Newswire

Apr 14, 2021

08:31AM EDT I-Mab Announces Selected Poster Presentation Of CD73 Antibody Uliledlimab At American Society Of Clinical Oncology 2021 Annual Meeting Benzinga

08:30AM EDT I-Mab Announces Selected Poster Presentation of CD73 Antibody GlobeNewswire Inc

Apr 7, 2021

10:23AM EDT I-MAB Shares Flat Ahead Of Co's R&D Day Event Beginning 14:00 China Standard Time; English Event To Take Place April 26, 2021 Starting At 8 a.m. Benzinga

Apr 6, 2021

10:16AM EDT Shanghai Genchem Announces Global Collaboration On Bispecific Antibodies Benzinga

08:01AM EDT I-Mab And ABL Bio Announce First Patient Dosed In Phase 1 Trial Of Bispecific Antibody TJ-L14B/ABL503 In Patients With Advanced Or Metastatic Solid Tumors Benzinga

08:00AM EDT I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of GlobeNewswire Inc

Mar 31, 2021

08:00AM EDT I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologic, today announced its participation in the following conferences in April. Details of the conferences and management presentation are as follows: GlobeNewswire Inc

Mar 30, 2021

08:04AM EDT I-Mab, ABL Bio Receive U.S. FDA Approval To Initiate Phase 1 Trial Of Bispecific Antibody TJ-CD4B/ABL111 In Patients With Advanced Or Metastatic Solid Tumors Benzinga

08:00AM EDT I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 GlobeNewswire Inc

Mar 29, 2021

07:00AM EDT -- 18 significant clinical milestones achieved since the Companys IPO in January 2020, with multiple important data readouts for lemzoparlimab (TJC4), uliledlimab (TJD5) and other clinical assets expected in 2021 GlobeNewswire Inc

04:16AM EDT Earnings Scheduled For March 29, 2021 Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 24, 2021

08:00AM EDT Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts GlobeNewswire Inc

Mar 19, 2021

04:24PM EDT I-Mab Files For A Prospectus Supplement To Register 19.050M Common Stock Benzinga

04:20PM EDT I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse GlobeNewswire Inc

Mar 15, 2021

11:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2021 Benzinga

10:54AM EDT I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation Benzinga

06:50AM EDT Needham Initiates Coverage On I-MAB with Buy Rating, Announces Price Target of $75 Benzinga

Mar 11, 2021

08:02AM EST I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting Benzinga

08:00AM EST I-Mab To Present Differentiated Mechanism of Action and GlobeNewswire Inc

Mar 10, 2021

08:32AM EST I-Mab Says Signs Global Drug Discovery, Development Agreement With Complix To Develop Cell Penetrating Alphabodies Against 2 Intracellular Immuno-Oncology Targets Benzinga

08:04AM EST I-Mab Says Launches Discovery Initiative To Expand Transformational Immuno-Oncology Pipeline Benzinga

08:00AM EST - New Initiative is part of I-Mabs long-term strategy to drive innovation and scientific leadership in immuno-oncology-New collaborations signed will allow I-Mab access to cutting edge technology platforms to develop novel drug molecules-I-Mab continues to focus on delivering on key clinical programs while building pipeline of next generation assets GlobeNewswire Inc

Mar 3, 2021

09:01AM EST H.C. Wainwright Maintains Buy on I-MAB, Raises Price Target to $75 Benzinga

08:02AM EST I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate PR Newswire

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

Feb 25, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2021 Benzinga

08:24AM EST I-Mab Reports First Patient Dosed In China Phase 3 Study Of Eftansomatropin Alfa In Pediatric Patients With Growth Hormone Deficiency Benzinga

08:18AM EST I-Mab Doses 1st Patient In China Phase 3 Study Of TJ101 In Pediatric Patients With Growth Hormone Deficiency RTTNews

08:01AM EST I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin PR Newswire

06:21AM EST Piper Sandler Initiates Coverage On I-MAB with Overweight Rating, Announces Price Target of $75 Benzinga

Feb 24, 2021

08:01AM EST I-Mab Announces Upcoming Participation at March Conferences PR Newswire

Feb 10, 2021

08:10AM EST I-Mab Reports China NMPA Clearance For Phase 1 Study Of TJ210/MOR210 In Patients With Advanced Solid Tumors RTTNews

08:05AM EST I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors Benzinga

08:02AM EST I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in PR Newswire

Feb 9, 2021

08:01AM EST Secondary ADS Offering Of Pre-IPO Shareholders of I-Mab Priced At $54/ADS Benzinga

08:01AM EST Registered Secondary Public Offering of American Depositary Shares by Certain PR Newswire

Feb 5, 2021

05:28PM EST Proposed Registered Secondary Public Offering of American Depositary Shares by PR Newswire

08:03AM EST I-Mab Reports First Patient Dosed In Combo Study Of CD73 Antibody In China; Highlights Topline Results From Phase 1 Study In US Benzinga

08:02AM EST I-Mab Announces Multiple Clinical Advancements Of Differentiated CD73 Antibody Uliledlimab In China And U.S. RTTNews

08:01AM EST I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 PR Newswire

Feb 4, 2021

08:14AM EST I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China Benzinga

08:02AM EST I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in PR Newswire

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Feb 2, 2021

08:05AM EST The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 25, 2021

04:07PM EST I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer Benzinga

04:05PM EST I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of PR Newswire

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 6, 2021

07:31AM EST The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping Benzinga

Jan 5, 2021

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

Dec 23, 2020

08:00AM EST I-Mab Announces Upcoming Participation at January Conferences PR Newswire

Dec 14, 2020

08:02AM EST I-Mab Added to Nasdaq Biotechnology Index PR Newswire

Dec 7, 2020

10:10AM EST Benzinga's Top Upgrades, Downgrades For December 7, 2020 Benzinga

06:59AM EST HC Wainwright & Co. Initiates Coverage On I-MAB with Buy Rating, Announces Price Target of $55 Benzinga

Dec 4, 2020

08:04AM EST I-Mab Highlights Advancement Of Clinical Development Of Anti-CD47 Monoclonal Antibody Lemzoparlimab In US And China Benzinga

08:01AM EST I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody PR Newswire

Dec 1, 2020

04:24PM EST I-Mab Files Shelf Registration Statement for PIPE Investors PR Newswire

04:15PM EST I-MAB Announces Selling Shareholders May Offer, From Time To Time, Up To 25.1M Ordinary Shares Benzinga

08:02AM EST I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific PR Newswire

Nov 13, 2020

05:10AM EST I-Mab to Hold Investor Call and Expand Clinical Data Analysis on Efficacy PR Newswire

Nov 11, 2020

08:02AM EST I-Mab Announces Preclinical Data On Differentiated Anti-C5aR Antibody TJ210/MOR210 RTTNews

08:02AM EST I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody PR Newswire

Nov 9, 2020

08:24AM EST I-Mab Reports Phase 1 Trial Data Of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab RTTNews

08:22AM EST I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting Benzinga

08:12AM EST I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 PR Newswire

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 28, 2020

08:00AM EDT I-Mab Announces Upcoming Participation at November Conferences PR Newswire

Oct 27, 2020

08:18AM EDT I-Mab To Present Preclinical Data Of TJ210 At 2020 Society For Immunotherapy Of Cancer (SITC) Annual Meeting Benzinga

08:06AM EDT I-Mab To Present Preclinical Data Of TJ210 At The 2020 SITC Annual Meeting RTTNews

08:05AM EDT I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for PR Newswire

Oct 15, 2020

08:02AM EDT I-Mab To Present Phase 1 Data Of Lemzoparlimab At 2020 Society For Immunotherapy Of Cancer Annual Meeting RTTNews

08:01AM EDT I-Mab to Present Phase 1 Data of Lemzoparlimab at the 2020 Society for PR Newswire

Sep 30, 2020

03:55PM EDT Mid-Afternoon Market Update: Dow Jumps 350 Points; Iterum Therapeutics Shares Spike Higher Benzinga

08:03AM EDT I-Mab Receives China CDE Approval To Initiate Phase 3 Clinical Trial Of Eftansomatropin In Pediatric Patients With Growth Hormone Deficiency Benzinga

08:01AM EDT I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of PR Newswire

Sep 21, 2020

08:15AM EDT I-Mab Announces China NMPA Clearance For Phase 1 Clinical Trial Of Lemzoparlimab In Relapsed Or Refractory Advanced Lymphoma Benzinga

08:12AM EDT I-Mab : China Oks For Phase 1 Clinical Trial Of Lemzoparlimab In Relapsed Or Refractory Advanced Lymphoma RTTNews

08:01AM EDT I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of PR Newswire

Sep 17, 2020

04:06PM EDT MorphoSys, I-Mab Announces FDA Clearance Of IND Application For MOR210/TJ210 In Patients With Advanced Cancer Benzinga

04:05PM EDT MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 PR Newswire

Sep 8, 2020

08:01AM EDT I-Mab Announces Upcoming Participation at September Conferences PR Newswire

Sep 4, 2020

09:49AM EDT Shares of I-Mab (IMAB) jumped over 10% on Friday morning after the Chinese biotech company announced a collaboration deal with AbbVie Inc. (ABBV) to develop and sell I-Mab's lemzoparlimab for the treatment of multiple cancers. The deal could be worth more than $2 billion. RTTNews

07:14AM EDT AbbVie To License I-Mab's Anti-CD47 Monoclonal Antibody RTTNews

07:06AM EDT I-Mab Announces $418M Private Placement with Hillhouse Capital-Led Consortium Benzinga

07:04AM EDT I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium Benzinga

07:04AM EDT UPDATE: AbbVie And I-Mab To Collaborate On Development And Commercialization Of I-Mab's Anti-CD47 Monoclonal Antibody Lemzoparlimab Benzinga

07:03AM EDT I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium Benzinga

07:03AM EDT I-Mab Unveils $418 Mln Private Placement With Hillhouse Capital-Led Consortium RTTNews

07:03AM EDT AbbVie And I-Mab Sign Global Collaboration Agreement For Development Of Lemzoparlimab RTTNews

07:01AM EDT I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led PR Newswire

07:01AM EDT AbbVie and I-Mab Enter Into Partnership For Differentiated Immuno-Oncology Therapy; I-Mab To Receive $180M Upfront Payment Benzinga

07:00AM EDT AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated PR Newswire

Aug 31, 2020

07:16AM EDT I-Mab 6-month Net Loss RMB 582.9 Mln Vs. Net Loss RMB 857.3 Mln Last Year RTTNews

07:05AM EDT I-Mab 1H EPS $(0.41) Benzinga

07:01AM EDT I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides PR Newswire

04:01AM EDT Earnings Scheduled For August 31, 2020 Benzinga

Aug 30, 2020

08:24AM EDT The Week Ahead In Biotech (Aug. 30- Sept. 5): Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing Benzinga

Aug 26, 2020

09:42AM EDT Benzinga's Top Upgrades, Downgrades For August 26, 2020 Benzinga

07:06AM EDT CMB International Initiates Coverage On I-MAB with Buy Rating, Announces Price Target of $41.3 Benzinga

Aug 17, 2020

08:22AM EDT I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China Benzinga

08:01AM EDT I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in PR Newswire

Aug 6, 2020

08:30AM EDT I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and PR Newswire

Aug 4, 2020

08:24AM EDT I-Mab Announces China National Medical Products Administration Has Accepted Pivotal Trial Application For Eftansomatropin Benzinga

08:19AM EDT China Accepts IND Application For Eftansomatropin Pivotal Trial In Pediatric Patients With Growth Hormone Deficiency RTTNews

08:17AM EDT China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in PR Newswire

Jul 28, 2020

08:01AM EDT I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as PR Newswire

Jul 27, 2020

06:13AM EDT Cantor Fitzgerald Initiates Coverage On I-MAB with Overweight Rating, Announces Price Target of $50 Benzinga

Jul 15, 2020

04:15PM EDT I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million PR Newswire

.dark-mode .NJD3pC{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .NJD3pC{ color: #333333; background-color: white; border: 2px solid #333333; }IMABI-MABstock NASDAQ ADR

IMAB
I-MAB
stock NASDAQ ADR